Disclosed herein is a novel p53 complex and a collection of compounds that can tightly associate with p53 to efficiently rescue wildtype p53 structure and function, and the methods of making and using the complex and the compounds, including for diagnosis, prognosis, and treatment of p53 related disorders such as cancer and aging.

Provided are methods for treating, ameliorating, reversing and/or preventing a Helicobacter pylori (H. pylori) infection in an individual in need thereof, comprising: administering to the individual in need thereof a therapeutic combination comprising: (a) a composition comprising or consisting of: vonoprazan or a vonoprazan fumarate, or a 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine monofumarate, or a 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methyl-methanamine fumarate), optionally TAKECAB™; and (b) an antimicrobial or antibiotic drug or composition.

Provided are methods for treating, ameliorating, reversing and/or preventing a Helicobacter pylori (H. pylori) infection in an individual in need thereof, comprising: administering to the individual in need thereof a therapeutic combination comprising: (a) a composition comprising or consisting of: vonoprazan or a vonoprazan fumarate, or a 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine monofumarate, or a 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methyl-methanamine fumarate), optionally TAKECAB™; and (b) an antimicrobial or antibiotic drug or composition.

Disclosed are compositions comprising polymeric nanoparticles and methods of using the same. The polymeric nanoparticles can be conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein. The polymeric nanoparticles can also comprises an imaging compound and/or a therapeutic agent encapsulated in the hydrophobic interior of the nanoparticle. A cancer therapeutic composition comprising the nanoparticle is also disclosed. The disclosed nanoparticles can be used to target and deliver imaging and/or therapeutic compounds to cancer cells, thereby identifying and/or treating a solid tumor cell target. Methods for treating cancer, such as lung cancer, using the polymeric nanoparticles are also disclosed.

Liquid formulations or syrup comprise an over-the-counter API ingredient or a dietary supplement ingredient. The ingredients are present in concentrated amounts. Multiple doses of the syrups may be packaged in relatively small bottles, such as bottles with a capacity of 100 ml or less.

A pharmaceutical composition generally includes a compound that reduces H.sub.2S in the gut of a subject and a pharmaceutically acceptable carrier. In some embodiments, the compound that reduces H.sub.2S in the gut of a subject can include magnesium or a salt thereof, bismuth or a salt thereof, molybdenum or a salt thereof, zinc or a salt thereof, iron or a salt thereof, nickel or a salt thereof, nitrate or a salt thereof, cobinamide or a salt thereof, a heme protein, an antimicrobial, an antibiotic, a prebiotic, a probiotic, or a synbiotic.

In another aspect, a method of detecting H.sub.2S-mediated hyperdynamic circulation, or a consequence thereof in a subject having, or at risk of having, H.sub.2S-mediated hyperdynamic circulation generally includes obtaining a biological sample from the subject, measuring H.sub.2S in the sample, and identifying the subject as having H.sub.2S-mediated hyperdynamic circulation if the H.sub.2S measured in the sample is greater than a predetermined threshold. In some embodiments, the biological sample can be plasma or blood. In some of these embodiments, the predetermined threshold is a plasma H.sub.2S concentration of 45 M. In other embodiments, the predetermined threshold is a baseline plasma H.sub.2S concentration measured from a previous sample from the subject.

A pharmaceutical composition generally includes a compound that reduces H.sub.2S in the gut of a subject and a pharmaceutically acceptable carrier. In some embodiments, the compound that reduces H.sub.2S in the gut of a subject can include magnesium or a salt thereof, bismuth or a salt thereof, molybdenum or a salt thereof, zinc or a salt thereof, iron or a salt thereof, nickel or a salt thereof, nitrate or a salt thereof, cobinamide or a salt thereof, a heme protein, an antimicrobial, an antibiotic, a prebiotic, a probiotic, or a synbiotic.

In another aspect, a method of detecting H.sub.2S-mediated hyperdynamic circulation, or a consequence thereof in a subject having, or at risk of having, H.sub.2S-mediated hyperdynamic circulation generally includes obtaining a biological sample from the subject, measuring H.sub.2S in the sample, and identifying the subject as having H.sub.2S-mediated hyperdynamic circulation if the H.sub.2S measured in the sample is greater than a predetermined threshold. In some embodiments, the biological sample can be plasma or blood. In some of these embodiments, the predetermined threshold is a plasma H.sub.2S concentration of 45 M. In other embodiments, the predetermined threshold is a baseline plasma H.sub.2S concentration measured from a previous sample from the subject.

Novel mp53 rescue compounds and the pharmaceutical composition, and methods of treating a p53 disorder.

Novel mp53 rescue compounds and the pharmaceutical composition, and methods of treating a p53 disorder.

Novel mp53 rescue compounds and the pharmaceutical composition, and methods of treating a p53 disorder.